DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Adalimumab Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

The sales of Adalimumab increased significantly in 2020, reaching approximately CNY 101.11 million (2019 sales revenue is CNY 14.15 million), and the CAGR is around 38% from 2016 to 2020.

Therefore, the analyst analyzes that with the emergence of generic drugs, the choice of drugs increases. Therefore, the price of drugs will decrease. Coupled with the strict control of adjuvant drugs and the improvement of medical insurance policies, Adalimumab is expected to be more popular in China in 2021-2025, and sales will also increase accordingly.

In 2010, Adalimumab entered the Chinese market. Its original drug is produced by AbbVie Inc., under the brand name HUMIRA.

The sales of HUMIRA is ranking at Top one among all pharmaceutical products since it is used for a huge amount of disease treatments (such as treatment of arthritis, Crohn's disease, ulcerative colitis, and so on). However, unlike the EU and the NA market, Adalimumab is not popular in the Chinese market.

From 2016 to 2019, the sales of Adalimumab decreased gradually due to three reasons. One is because it is not included in the medical insurance, while its price is about CNY7,600 per injection, which makes a patient spend about CNY10,000 to CNY20,000 on the medicine.

Secondly, Adalimumab has far fewer indications approved in China than that in the EU and the NA countries (including the indications for rheumatoid arthritis approved in 2010, the indications for ankylosing spondylitis approved in 2013, and the indications for psoriasis approved in 2017). Lastly, adjuvant drugs have dominated the Chinese drug sales market for a long period.

On the other hand, after the declining sales from 2016 to 2019, the sales of Adalimumab in the Chinese market have increased by about 7 times in 2020 compared to the previous year. The substantial increase is mainly due to the improvement of medical insurance policies and the rectification of the abuse of adjuvant drugs. Besides, more generic drugs appear in the market since the patent of HUMIRA is about to expire.

Although Abbvie Inc. successfully postponed the threat of US biosimilars to 2023, it lost its patent protection in Europe on October 16, 2018. In China, 28 companies have filed generic drug applications for Adalimumab biosimilars in 2019. In 2020, three companies have launched generic drugs, namely Zhejiang Hisun Pharmaceutical Co., Ltd., Bio- Thera Solutions, Ltd., and Innovent Biologics (Suzhou) Co., Ltd.

Topics Covered:

• The impact of COVID-19 on China's adalimumab market
• Sales value and volume of China's adalimumab 2016-2020
• Competitive landscape of China's adalimumab market
• Prices of adalimumab in China
• Prices of adalimumab in China by regions and manufacturers
• Analysis of factors affecting the development of China's adalimumab market
• Prospect of China's adalimumab market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Adalimumab

1.1 Indications for Adalimumab

1.2 Development of Adalimumab in China

1.3 Governmental Approval of Adalimumab in China

1.4 The Impact of COVID-19 on Adalimumab sales in China

2 Sales of Adalimumab in China, 2016-2020

2.1 Sales Value of Adalimumab

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Adalimumab

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Adalimumab by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Adalimumab Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Adalimumab Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 AbbVie Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of HUMIRA (AbbVie's Adalimumab) in China

3.3 Zhejiang Hisun Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Anjianning (Hisun's Adalimumab) in China

3.4 Bio-Thera Solutions, Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of OLETLI (Bio-Thera's Adalimumab) in China

3.5 Innovent Biologics (Suzhou) Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of SULINNO(Innovent's Adalimumab) in China

4 Prices of Adalimumab for Different Manufacturers in China, 2020-2021

4.1 AbbVie Ltd. (HUMIRA)

4.2 Zhejiang Hisun Pharmaceutical Co., Ltd. (Anjianning)

4.3 Bio-Thera Solutions, Ltd. (OLETLI)

4.4 Innovent Biologics (Suzhou) Co., Ltd. (SULINNO)

5 Prospect of Chinese Adalimumab drug Market, 2021-2025

5.1 Influential Factors of Chinese Adalimumab Market Development

5.1.1 The Impact of COVID-19 on Chinese Adalimumab Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/gaxs9g

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900